DFDA

Mycophenolate Mofetil

Treatment for Acute Glomerulonephritis

Typical Dosage: 1-1.5 g twice daily

Effectiveness
70%
Safety Score
38%
Clinical Trials
100
Participants
15K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
1-1.5 g twice daily
Time to Effect
Weeks to 3 months
Treatment Duration
Months to years, often long-term
Evidence Quality
HIGH
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$2,000
Side Effect Mgmt:$1,500
Total Annual:$5,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$3,056/QALY
QALYs Gained
1.8
Outcome-Based Costs
Cost per Responder
$9,167
Cost per Remission
$13,750
Comparison vs Cyclophosphamide
Cost Difference
$-500/year
Less expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Mycophenolate Mofetil Outcomes

for Acute Glomerulonephritis

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
GI disturbances (nausea, diarrhea, abdominal pain)
+40%
Leukopenia
+18%
Increased risk of infection
+18%
Anemia
+8%
Teratogenic
+100%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov